Quarterly report pursuant to Section 13 or 15(d)

Significant Strategic Collaborations (Details Narrative)

v3.24.1.u1
Significant Strategic Collaborations (Details Narrative) - USD ($)
 3 Months Ended
Mar. 17, 2023
Aug. 02, 2022
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Royalty payments     $ 510,817 $ 605,844  
Research and development expenses     944,321 595,276  
Prepaid expenses and other current assets     552,043   $ 603,828
Revenues     510,817 605,844  
Volition [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Proceeds from collaborator   $ 26,000      
Collaborative Agreements [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues     0 0  
Takeda [Member] | Royalty Revenue [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Royalty payments     500 $ 600  
Catalent Pharma Solutions [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development expenses     2,500,000    
Prepaid expenses and other current assets     28,000   100,000
Other assets     300,000   300,000
Scripps Research [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development expenses $ 900,000   900,000    
Prepaid expenses and other current assets     100,000   400,000
University Of Virginia [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development expenses     100,000    
Prepaid expenses and other current assets     $ 29,000   $ 0